Pax7-IRES-CreERT2

Nomenclature

C57BL/6Smoc-Pax7em1(IRES-Cre-ERT2)Smoc

Cat. NO.

NM-KI-200099

Strain State

Repository Live

Export PDF

Gene Summary

Gene Symbol
Pax7

Synonyms

Pax-7

NCBI ID

18509

MGI ID

97491

Ensembl ID

ENSMUSG00000028736

Pubmed

Pax7

Human Ortholog

PAX7

Model Description

A IRES-Cre-ERT2 expression cassette was knocked into the Pax7 gene stop codon site. Pax7 is expressed in myogenic progenitor cells. Pax7 is essential for the myogenic potential, survival, and proliferation of myogenic progenitors. When crossed with a strain carrying a gene flanked by loxP sites, the flanked gene will be removed in cells expressing Pax7 after tamoxifen treatment.
Research Application：Cre recombinase tool

Validation Data

image.png

Fig. 1 CreERT2-mediated recombination in the muscle of Pax7CreERT2/+; Rosa26tdTomato/+ mouse. TdTomato(red) expression can be detected in the muscle satellite cells of Pax7CreERT2/+; Rosa26tdTomato/+ mouse after tamoxifen treatment. Some leakiness were detected prior to tamoxifen exposure.

image.png

Fig. 2 Detection of tdTomato(red) in various tissues of Pax7CreERT2/+; Rosa26tdTomato/+ mice. Tdtomato can not be detected in the brain, colon, eye, heart, intestine, kidney, lung, liver, pancreas, stomach, spleen, skin, salivary gland, testis or epididymis. (For more detailed information please contact our technical advisor.)


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more